Glazer Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMAA
Glazer Capital's DMAA Position: Q2 2026 in Review
Glazer Capital reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 40% in Q2 2026, selling an estimated $7.18M and leaving 999,899 shares worth $10.6M. The position accounts for 0.26% of the portfolio, ranked #77.
Glazer Capital first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $18.8M in Q4 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.
- Glazer Capital held 999,899 shares of Drugs Made In America Acquisition Corp worth $10.6M as of Q2 2026.
- Glazer Capital sold 678,507 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $7.18M.
- Drugs Made In America Acquisition Corp made up 0.26% of Glazer Capital's portfolio in Q2 2026, its #77 holding.
- Glazer Capital first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
- Glazer Capital's Drugs Made In America Acquisition Corp position peaked at $18.8M in Q4 2025.
- 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.
Based on Glazer Capital's 13F filing for Q2 2026, filed 17 Aug 2026.